popul
densiti
immun
statu
vector
virul
infect
nutrit
statu
sanit
genet
suscept
medic
manag
case
import
factor
influenc
incid
andor
sever
viru
infect
thu
preval
clinic
import
viru
infect
need
antivir
drug
differ
place
place
time
time
nation
world
health
statist
notif
diseas
give
index
incid
infect
viru
infect
notifi
statist
mislead
also
failur
notifi
sloth
part
physician
absenc
pathognomon
symptom
sign
error
diagnosi
assess
need
new
antivir
drug
consid
avail
safeti
effect
cost
altern
measur
includ
prevent
spread
infect
control
vector
immun
use
viral
vaccin
treatment
exist
antivir
drug
earli
start
treatment
acut
viru
infect
exist
drug
give
best
result
clinic
diagnosi
uncertain
accur
rapid
viru
diagnosi
paramount
import
mani
viru
infect
asymptomat
trivial
import
without
sequela
howev
new
improv
antivir
drug
need
prevent
andor
treatment
number
signific
condit
caus
virus
present
adequ
control
includ
upper
lower
respiratori
tract
infect
influenza
chronic
hepat
gastroenter
infecti
mononucleosi
measl
rabi
haemorrhag
fever
wart
furthermor
drug
might
prove
therapeut
valu
prevent
treatment
virusassoci
tumour
hepatoma
nasopharyng
carcinoma
burkitt
lymphoma
kaposi
sarcoma
possibl
carcinoma
cervix
antivir
vaccin
immunoglobulin
need
antivir
drug
directli
depend
clinic
import
preval
viru
infect
avail
safeti
effect
accept
cost
exist
antivir
agent
includ
immunoglobulin
vaccin
procedur
design
control
vector
infect
mani
viru
infect
clinic
symptom
appear
rel
late
appear
viral
replic
ceas
antivir
could
therapeut
valu
infect
symptom
patholog
chang
develop
presenc
viral
replic
howev
prophylact
treatment
contact
anoth
potenti
import
indic
infect
clinic
import
viru
infect
assess
accord
rate
mortal
morbid
frequenc
longterm
sequela
thu
exampl
fatal
outcom
associ
clinic
rabi
herp
enceph
confer
infect
import
differ
rhinovirus
preval
infect
highli
variabl
depend
mani
factor
includ
popul
densiti
immun
statu
genet
suscept
geograph
locat
sanit
viru
virul
medic
manag
case
particular
refer
quarantin
procedur
prevent
transmiss
clearli
preval
infect
chang
new
vaccin
develop
accord
success
programm
immun
control
vector
implement
preval
infect
assess
notif
infecti
diseas
recognis
notif
base
clinic
diagnos
sometim
erron
failur
notifi
atyp
asymptomat
infect
often
go
unrecognis
exampl
proport
case
poliomyel
paralysi
vari
infect
influenza
may
produc
symptom
common
cold
without
signific
system
ill
ratio
case
rubella
without
rash
report
vari
nevertheless
britain
nation
statist
indic
measl
infect
jaundic
influenza
target
control
tabl
notif
statist
avail
gener
practic
cover
sampl
popul
approxim
person
would
add
common
cold
varicella
zoster
viru
infect
possibl
rubella
mump
tabl
viru
infect
notifi
although
preval
caus
uniqu
clearcut
clinic
syndrom
eg
respiratori
syncyti
viru
regard
nation
medic
import
eg
mump
import
special
circumst
exampl
pregnanc
patient
depress
immun
system
unabl
mount
normal
immun
respons
infect
eg
cytomegaloviru
small
number
antivir
drug
licens
see
tabl
highli
activ
toxic
compound
limit
use
topic
applic
treatment
lifethreaten
condit
other
clinic
effect
less
clearcut
new
era
antivir
drug
herald
introduct
acyclovir
compound
highli
effect
herp
group
virus
notabl
herp
simplex
varicella
zoster
virus
mode
action
protect
uninfect
cell
given
system
essenti
without
signific
sideeffect
infectionspecif
immunoglobulin
avail
measl
hepat
b
varicelia
zoster
rabi
virus
immunoglobulin
provid
temporari
protect
infecti
diseas
import
use
exampl
protect
travel
hepat
howev
result
treatment
infecti
viru
diseas
unimpress
consider
need
antivir
agent
must
take
account
avail
safe
effect
viral
vaccin
unit
kingdom
exampl
nation
programm
vaccin
poliomyel
type
ii
iii
measl
rubella
girl
addit
vaccin
recommend
subject
special
risk
influenza
hepat
b
yellow
fever
rabi
vaccin
avail
travel
mump
vaccin
licens
recommend
sinc
consid
morbid
sequela
mump
infect
signific
viral
vaccin
either
live
inactivat
measl
rubella
mump
yellow
fever
oral
poliomyel
vaccin
live
vaccin
subject
inocul
attenu
infect
elicit
protect
immun
respons
long
lifelong
durat
caus
symptom
natur
infect
except
oral
poliomyel
vaccin
singl
dose
vaccin
constitut
primari
immun
cours
vaccin
highli
effect
develop
countri
howev
sinc
may
inactiv
temperatur
mainten
cold
chain
manufactur
vaccine
paramount
import
cold
chain
may
breach
develop
countri
particularli
high
ambient
temperatur
comparison
inactiv
viru
vaccin
exampl
influenza
rabi
inactiv
poliomyel
hepat
b
usual
requir
sever
dose
primari
immun
cours
elicit
less
durabl
immun
respons
requir
administr
reinforc
dose
polio
viru
replic
occur
intestin
tract
lymph
node
follow
viraemia
sometim
nervou
system
involv
lead
paralysi
often
nervou
system
involv
occur
infect
biphas
minor
ill
first
phase
viraemia
remiss
day
follow
recurr
fever
develop
paralysi
mening
immunoglobulin
littl
valu
unless
given
viraemia
occur
stage
case
readili
identifi
oral
poliomyel
vaccin
highli
effect
poliomyel
present
threat
develop
countri
britain
annual
uptak
vaccin
maintain
concern
safeti
simultan
administ
whoop
cough
vaccin
reduc
uptak
latter
less
howev
oral
poliomyel
vaccin
total
safe
vaccineassoci
paralysi
occur
recipi
contact
vaccine
estim
frequenc
respect
per
million
dose
vaccin
administ
use
inactiv
poliomyel
vaccin
would
obviat
vaccineassoci
paralysi
possibl
uptak
level
low
current
seen
oral
vaccin
would
insuffici
prevent
outbreak
mani
countri
africa
asia
continent
america
exclud
unit
state
canada
report
mean
case
paralyt
poliomyel
annual
paccaud
comment
world
may
divid
two
groupscountri
nationwid
poliomyel
vaccin
campaign
incid
approach
zero
countri
without
programm
incid
increas
latter
improv
live
standard
associ
delay
age
infect
occur
lead
increas
incid
paralysi
furthermor
tropic
countri
live
vaccin
frequent
shown
elicit
poor
seroconvers
rate
result
attribut
breach
cold
chain
interf
enteroviru
infect
andor
inactiv
vaccin
viru
antivir
agent
present
saliva
howev
mass
immun
programm
effect
control
outbreak
poliomyel
within
twelv
day
initi
thu
develop
antipoliomyel
viru
drug
seem
secondari
import
implement
aggress
poliomyel
vaccin
programm
use
either
live
kill
vaccin
measl
viraemia
occur
day
infect
first
catarrh
symptom
develop
th
day
rash
appear
day
simultan
end
viru
replic
develop
antibodi
develop
countri
measl
rare
lifethreaten
immun
compet
children
carri
signific
morbid
mainli
due
bacteri
superinfect
respiratori
tract
also
occasion
case
enceph
high
measl
mortal
rate
seen
malnourish
children
tropic
develop
countri
children
immunecompromis
unit
state
health
author
aim
erad
measl
requir
children
attend
school
immun
result
previou
natur
infect
vaccin
case
measl
report
whole
unit
state
comparison
almost
england
wale
unit
state
england
wale
respect
case
notifi
measl
vaccin
uptak
usa
wherea
britain
nation
childhood
encephalopathi
studi
demonstr
vaccin
children
time
like
develop
enceph
day
vaccin
unvaccin
control
children
nevertheless
estim
risk
enceph
within
day
vaccin
significantli
less
associ
natur
infect
time
western
european
countri
approach
control
measl
achiev
unit
state
antimeasl
compound
would
valu
treatment
children
develop
countri
children
seriou
measl
develop
countri
children
immunecompromis
howev
sinc
viru
replic
ceas
rash
appear
earli
diagnosi
treatment
would
critic
addit
compound
might
effect
manag
patient
subacut
scleros
panenceph
rare
condit
caus
persist
measl
infect
central
nervou
system
give
rise
progress
neurolog
dysfunct
death
rubella
mild
infect
without
signific
sequela
would
bare
worth
prevent
treatment
teratogen
effect
pregnanc
follow
outbreak
rubella
unit
state
new
york
univers
medic
center
care
children
congenit
defect
follow
matern
rubella
deaf
blind
heart
diseas
psychomotor
retard
death
consequ
estim
matern
child
care
typic
surviv
children
would
cost
million
live
vaccin
safe
effect
avail
uptak
young
children
reduc
incid
congenit
rubella
unit
state
howev
far
rubella
vaccin
programm
europ
shown
littl
effect
uk
nation
congenit
rubella
surveil
programm
document
case
confirm
suspect
congenit
rubella
decad
inclus
gave
histori
ill
contact
would
therefor
present
candid
antivir
therapi
howev
signific
addit
number
risk
pregnanc
termin
clearli
present
limit
individu
import
need
antirubella
viru
chemotherapi
nevertheless
develop
compound
specif
use
pregnanc
would
present
difficulti
inclus
britain
million
day
certifi
incapac
influenza
male
alon
influenza
pose
greater
risk
patient
chronic
respiratori
ill
chronic
diseas
normal
popul
control
influenza
vaccin
present
special
problem
abil
infuenza
virus
recombin
give
new
antigen
type
evad
immun
gener
previou
natur
infect
vaccin
major
antigen
chang
preced
worldwid
pandem
smaller
antigen
chang
associ
smaller
outbreak
inactiv
influenza
vaccin
clearli
protect
infect
homolog
strain
propens
wild
viru
undergo
antigen
chang
make
vaccin
influenza
less
certain
effect
procedur
case
virus
gener
recommend
vaccin
restrict
special
risk
group
drug
antiinfluenza
viru
activ
avail
amantadin
inhibit
penetr
influenza
viru
strain
host
cell
shown
placebocontrol
trial
prevent
infect
subtyp
h
therapeut
trial
amantadin
shown
give
rapid
recoveri
curtail
amount
durat
viru
shed
amantadin
also
use
treatment
parkinson
diseas
receiv
wide
accept
antivir
agent
probabl
incomplet
effect
occurr
minor
side
effect
absenc
activ
influenza
viru
b
strain
presenc
outbreak
influenza
merit
prophylact
administr
amantadin
high
risk
patient
contrast
advantag
use
sporad
case
influenza
less
clear
sinc
ill
caus
b
strain
distinguish
clinic
ground
rapid
laboratori
techniqu
identifi
caus
viru
routin
done
practition
know
whether
individu
infect
b
strain
even
agent
rimantadin
analogu
amantadin
least
equival
prophylact
therapeut
activ
caus
fewer
side
effect
ribavirin
administ
aerosol
shown
effect
prevent
infect
b
strain
also
treatment
experiment
infect
respiratori
syncyti
viru
despit
avail
amantadin
develop
rimantadin
ribavirin
remain
need
effect
broad
spectrum
antivir
agent
use
prevent
treat
influenza
viral
respiratori
infect
term
viral
hepat
appli
sever
clinic
similar
diseas
entiti
hepat
caus
picornaviru
occur
commonli
popul
serolog
evid
infect
adulthood
agent
transmit
faecoor
rout
infect
usual
acut
symptom
fever
malais
anorexia
mild
abdomin
discomfort
jaundic
although
asymptomat
anicter
case
occur
mortal
rate
low
chronic
infect
lead
cirrhosi
demonstr
yet
vaccin
hepat
licens
shortterm
protect
infect
may
achiev
administr
immun
serum
globulin
recommend
certain
class
contact
accord
degre
risk
sinc
clinic
symptom
appear
viru
shed
ceas
develop
antihepat
viru
agent
seem
import
target
hepat
b
caus
hepadnaviru
insidi
infect
symptom
anorexia
nausea
vomit
malais
abdomin
pain
jaundic
joint
involv
infect
transmit
infect
serum
blood
inocul
hypoderm
needl
abraid
skin
mucou
membran
patient
develop
chronic
carrier
state
may
either
asymptomat
associ
activ
liver
diseas
patient
chronic
infect
may
develop
cirrhosi
liver
primari
hepatocellular
cancer
unit
state
case
hepat
b
infect
report
annual
although
estim
case
notifi
death
hepat
cirrhosi
death
due
primari
hepatocellular
carcinoma
respect
attribut
hepat
b
incid
may
lower
unit
kingdom
sinc
england
wale
case
infect
jaundic
notifi
incid
hepat
b
higher
popul
exampl
chines
infect
earli
life
frequent
follow
signific
incid
primari
hepatocellular
carcinoma
hepat
b
vaccin
recent
becom
avail
recommend
immun
class
subject
special
risk
infect
eg
drug
addict
haemophiliac
homosexu
mental
defect
medic
paramed
staff
care
shortterm
protect
hepat
b
may
achiev
administr
hepat
b
immunoglobulin
altern
immun
serum
globulin
recommend
contact
human
hepat
b
viru
readili
propag
tissu
cultur
anim
anim
model
infect
relat
hepat
virus
develop
therefor
assess
antivir
activ
test
agent
carri
directli
human
subject
monitor
viru
marker
infect
antivir
effect
interferon
adenosin
arabinosid
adenosin
arabinosid
monophosph
acyclovir
combin
agent
studi
patient
chronic
infect
agent
shown
affect
marker
viru
replic
shortterm
howev
viru
replic
usual
return
pretreat
level
shortterm
antivir
therapi
stop
two
import
target
antivir
therapi
condit
convert
infecti
carrier
noninfecti
carrier
erad
infect
therebi
prevent
liver
damag
longterm
sequela
cirrhosi
cancer
human
subject
clinic
manifest
rabi
almost
alway
fatal
contin
free
rabi
except
australia
antarctica
rabi
report
european
countri
year
period
laboratoryconfirm
case
anim
postexposur
treatment
given
million
peopl
despit
precaut
death
rabi
europ
period
case
document
algeria
bangladesh
burma
rabi
develop
subject
follow
bite
infect
anim
incub
period
week
viru
invad
central
nervou
system
travel
along
nerv
site
injuri
caus
convuls
coma
death
postexposur
treatment
rabi
vaccin
specif
immunoglobulin
effect
given
earli
earli
treatment
experiment
infect
monkey
human
leucocyt
interferon
administ
intramuscularli
cerebrospin
fluid
increas
surviv
comparison
control
human
case
treat
interferon
without
appar
improv
antivir
agent
activ
rabi
would
therefor
consider
interest
sever
herpetovirida
occur
commonli
human
herp
simplex
viru
varicella
zoster
viru
cytomegaloviru
epsteinbarr
viru
characterist
latenc
primari
infect
herp
simplex
viru
hsv
caus
spectrum
diseas
rang
high
mortal
rate
enceph
dissemin
neonat
herp
moder
morbid
herp
kerat
genit
herp
less
consequ
herp
labiali
cold
sore
classic
hsv
type
viru
caus
cold
sore
case
kerat
encephalopathi
type
ii
viru
caus
genit
herp
except
enceph
recurr
episod
infect
common
condit
orofaci
mucocutan
herpet
lesion
frequent
immunecompromis
patient
treatment
cytotox
immunesuppress
drug
malign
diseas
follow
cardiac
renal
bone
marrow
transplant
immun
suppress
remain
unchang
may
lead
persist
lesion
dissemin
infect
sometim
death
attempt
made
develop
inactiv
subunit
hsv
vaccin
yet
licens
shown
effect
prevent
experiment
infect
model
system
anim
given
infect
man
might
abl
prevent
primari
recurr
infect
sinc
recurr
infect
occur
presenc
circul
antibodi
vaccin
may
ineffect
reduc
frequenc
episod
suffer
ophthalm
prepar
idoxuridin
vidarabin
trifluorothymidin
acyclovir
shown
effect
treatment
herpet
eye
diseas
intraven
administ
vidarabin
shown
effect
treatment
hsv
enceph
neonat
herp
intraven
acyclovir
effect
treatment
hsv
enceph
prevent
treatment
hsv
infect
immunecompromis
patient
oral
topic
acyclovir
cream
formul
shown
effect
treatment
initi
recurr
genit
herp
topic
formul
treatment
herp
labiali
encourag
result
also
obtain
suppress
frequent
recurr
infect
oral
acyclovir
primari
infect
varicella
zoster
viru
vzv
caus
ofvaricella
chicken
pox
viru
remain
latent
primari
infect
failur
immun
surveil
recurr
lesion
present
herp
zoster
shingl
incid
shingl
increas
age
age
common
immun
system
compromis
rash
shingl
acut
pain
lesion
heal
patient
often
suffer
prolong
pain
postherpet
neuralgia
live
vzv
vaccin
develop
howev
chicken
pox
seriou
infect
immun
compet
children
prevent
treatment
clearli
merit
immunecompromis
howev
clinic
need
protect
immunecompromis
children
chicken
pox
need
antivir
treatment
chicken
pox
immunecompromis
shingl
immunecompromis
immun
compet
subject
acyclovir
vidarabin
interferon
shown
benefici
effect
control
trial
sever
drug
includ
bvdu
bromovinyldeoxyuridin
interest
activ
vzv
subject
otherwis
normal
infect
cytomegaloviru
cmv
almost
alway
asymptomat
howev
infect
pregnanc
may
infect
fetu
give
rise
fetal
damag
estim
congenit
infect
infant
would
born
unit
state
would
significantli
perman
handicap
neurodefici
clinic
manifest
cmv
infect
also
frequent
immunesuppress
allograft
recipi
becom
import
intens
immun
suppress
thu
cmv
infect
occur
patient
undergo
bone
marrow
transplant
john
hopkin
oncolog
center
infect
fatal
nonfat
present
death
caus
american
seri
renal
transplant
cmv
infect
occur
patient
account
death
graft
failur
febril
episod
episod
leucopenia
also
suggest
cmv
may
import
factor
immun
suppress
occur
acquir
immunedefici
syndrom
aid
condit
may
progress
kaposi
sarcoma
rational
suggest
patient
diseas
antibodi
cmv
control
cmv
infect
suppressor
cellular
immun
dna
earli
antigen
cmv
found
kaposi
sarcoma
cell
sinc
infect
normal
subject
usual
asymptomat
readili
amen
treatment
antivir
drug
attent
centr
prevent
use
vaccin
strain
live
vaccin
develop
concern
frequenc
congenit
infect
follow
reactiv
natur
infect
pregnanc
concern
support
report
second
infect
sibl
anxieti
possibl
oncogen
effect
cmv
nevertheless
cmv
infect
import
target
antivir
chemotherapi
particularli
immunecompromis
subject
combin
treatment
acyclovir
interferon
without
effect
treatment
cmv
infect
bone
marrow
transplant
recipi
although
placebocontrol
trial
interferon
prevent
cmv
infect
renal
transplant
recipi
patient
receiv
interferon
fewer
clinic
sign
cmv
infect
interferon
patient
placebo
patient
p
epsteinbarr
viru
ebv
caus
infecti
mononucleosi
glandular
fever
chronic
infect
lead
malais
fatigu
bout
fever
mani
month
infect
also
reactiv
immunecompromis
patient
epsteinbarr
viru
appear
aetiolog
factor
develop
burkitt
lymphoma
nasopharyng
carcinoma
respect
african
chines
popul
vaccin
yet
develop
viru
anoth
target
chemotherapi
mani
virus
caus
respiratori
ill
human
subject
tabl
unfortun
individu
virus
associ
clearcut
clinic
characterist
thu
virus
recov
children
upper
respiratori
infect
bronchiti
pneumonia
croup
influenza
parainfluenza
adeno
rhinoand
respiratori
syncyti
virus
recov
clinic
entiti
although
parainfluenza
viru
predomin
croup
influenza
adenovirus
upper
respiratori
infect
rhinovirus
bronchiti
respiratori
syncyti
viru
pneumonia
tabl
similarli
patient
cold
although
rhinovirus
predomin
virus
also
occur
frequent
view
wide
rang
ofaetiolog
rhinoviru
infect
major
caus
common
cold
import
econom
may
precipit
exacerb
bronchiti
sinus
otiti
media
predispos
patient
rhinovirus
grown
cell
cultur
adequ
anim
model
infect
avail
although
infect
rhinoviru
infect
could
prevent
vaccin
develop
polytyp
vaccin
cover
type
present
impract
number
synthet
compound
shown
inhibit
rhinoviru
tissu
cultur
enviroxim
administ
simultan
oral
intranas
rout
shown
exhibit
effect
prevent
experiment
rhinoviru
infect
human
subject
intranas
administ
ainterferon
effect
similarli
design
experi
although
prolong
treatment
caus
nasal
irrit
rhinoviru
infect
therefor
remain
target
develop
antivir
drug
prevent
treatment
respiratori
syncyti
diseas
chief
caus
sever
even
fatal
bronchiol
pneumonia
infant
ill
start
cold
follow
fever
short
breath
occurr
unusu
sever
ill
time
matern
circul
antibodi
still
present
suggest
iggantibodi
sensit
tissu
damag
viral
invas
infant
receiv
experiment
inactiv
vaccin
also
develop
particularli
sever
respiratori
ill
follow
infect
mechan
may
underli
sever
diseas
children
matern
igg
may
also
relat
fact
inactiv
vaccin
particular
antigen
fusion
protein
destroy
view
inadequaci
vaccin
sever
diseas
respiratori
syncyti
diseas
potenti
import
target
antivir
chemotherapi
way
respiratori
ill
caus
mani
virus
sever
speci
includ
rotaviru
adenoviru
caliciviru
coronaviru
involv
gastroenter
rotaviru
consid
rotavirus
infect
cell
line
small
intestin
occur
mani
avian
mammalian
speci
includ
man
respons
childhood
diarrhoea
differ
part
world
develop
countri
rotavirus
probabl
major
caus
diarrhoeal
death
infanc
estim
million
fatal
annual
develop
countri
infect
rare
fatal
sinc
dehydr
patient
given
adequ
time
hospit
care
nevertheless
viral
gastroenter
second
frequenc
common
cold
among
ill
affect
us
famili
techniqu
avail
rapid
identif
rotaviru
faec
also
suitabl
system
growth
tissu
cultur
recent
found
rotavirus
shown
contain
individu
segment
doublestrand
rna
specifi
polypeptid
genet
reassort
calf
human
rotavirus
detect
may
rotavirus
parallel
influenza
virus
relat
antigen
variabl
attempt
made
develop
rotaviru
vaccin
compound
antirotaviru
activ
found
benefici
result
oral
administr
gammaglobulin
infect
infant
suggest
safe
effect
agent
like
clinic
use
number
human
papilloma
virus
hpv
identifi
associ
deep
plantar
wart
common
wart
flat
wart
hpv
condylomata
acuminata
hpvh
laryng
papillomata
hpv
hpv
hpv
epidermodysplasia
verruciformi
hpv
also
implic
cofactor
develop
genit
cancer
number
report
indic
intralesion
system
administ
interferon
benefit
manag
patient
laryng
genit
wart
interferon
potent
antivir
materi
also
possess
properti
includ
anticellular
immunomodul
activ
extent
benefici
effect
interferon
treatment
hpv
infect
relat
nonantivir
properti
clear
furthermor
system
administ
interferon
regularli
caus
fever
chill
headach
unfortun
hpv
yet
grown
tissu
cultur
compound
antihpv
activ
would
consider
interest
import
viral
haemorrhag
fever
prospect
prevent
treatment
consid
recent
review
certain
virus
target
antivir
chemotherapi
detect
isol
continu
propag
cytopath
retrovirus
patient
acquir
immun
defici
syndrom
lead
prospect
develop
vaccin
antivir
agent
prevent
treatment
condit
review
make
claim
complet
import
virus
includ
new
virus
pathogen
man
continu
identifi
certain
point
worth
stress
antivir
drug
unlik
valu
treatment
symptom
appear
cessat
viru
replic
drug
may
use
prevent
infect
contact
vast
major
infect
earli
treatment
import
use
earli
treatment
demand
earli
diagnosi
either
clinic
base
upon
pathognomon
symptom
sign
rapid
viral
diagnost
techniqu
avail
specif
antivir
compound
latter
assum
greater
import
although
vaccin
measur
may
highli
effect
prevent
mani
infect
rememb
patient
vaccin
contraind
prevent
fail
exist
individu
need
safe
antivir
therapi
tabl
list
virus
avail
vaccin
specif
immunoglobulin
licens
antivir
drug
prevent
treatment
virus
shown
prevent
therapeut
agent
avail
six
vaccin
licens
prevent
six
specif
antivir
drug
three
infect
clear
need
new
better
agent
treatment
prevent
rhinoviru
influenza
respiratori
syncyti
respiratori
virus
hepat
b
epsteinbarr
cytomegalo
rabi
human
papilloma
rotavirus
